Leerink analyst Jason Gerberry says that the Patent Trial and Review Board's, or PTAB, ruling invalidating two of the three Teva's (TEVA) Copaxone 40mg patents in inter partes review litigation does not come as a "huge surprise" and believes a loss was largely implied by the Street. The analyst continues to see generic challengers being kept off the market until 2018. Furthermore, Gerberry believes the decision is a positive for Momenta (MNTA) as the company and Novartis (NVS) attempt to knock down Teva's patent in a district court case. Nonetheless, the analyst reiterates an Outperform rating on Teva's shares.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.